Yoo Hyun Dong, Chung Jong Chul, Park Ki Seok, Chung Seung Young, Park Moon Sun, Ryu Seungjun, Kim Seong Min
Department of Neurosurgery, Eulji University Hospital, Eulji University College of Medicine, Daejeon 35233, Republic of Korea.
Center for Neuromodulation, Department of Neurosurgery, NYU Langone Medical Center, New York, NY 11021, USA.
J Clin Med. 2023 Jul 3;12(13):4460. doi: 10.3390/jcm12134460.
This study investigates the long-term outcomes of clival chordoma patients treated with the endonasal transclival approach (ETCA) and early adjuvant radiation therapy. A retrospective review of 17 patients (2002-2013) showed a 10-year progression-free survival (PFS) rate of 67.4%, with the ETCA group showing fewer progressions and cranial neuropathies than those treated with combined approaches. The ETCA, a minimally invasive technique, provided a similar extent of resection compared to conventional skull-base approaches and enabled safe delivery of high-dose adjuvant radiotherapy. The findings suggest that ETCA is an effective treatment for centrally located clival chordomas.
本研究调查了采用经鼻经斜坡入路(ETCA)及早期辅助放疗的斜坡脊索瘤患者的长期预后。对17例患者(2002年至2013年)的回顾性研究显示,10年无进展生存率(PFS)为67.4%,与联合治疗方法相比,ETCA组的进展和颅神经病变较少。ETCA作为一种微创技术,与传统颅底入路相比,切除范围相似,且能够安全地进行高剂量辅助放疗。研究结果表明,ETCA是治疗位于中央的斜坡脊索瘤的有效方法。